Regulatory Johnson & Johnson’s multiple myeloma treatment secures EC approval Pharmaceutical Business ReviewThis decision provides a new therapeutic option for patients who have received at least one previous treatment.OncologyRead full story pharminent August 24, 2026 (Last updated: September 1, 2026) Pharmaceutical Business Review This decision provides a new therapeutic option for patients who have received at least one previous treatment. Oncology Read full story Post navigation Previous: UK MHRA authorises orforglipron private prescriptionNext: Roche commits to lean-mass preservation with Hanmi obesity deal Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026